Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
36.81
-0.61 (-1.63%)
Feb 21, 2025, 4:00 PM EST - Market closed
Kymera Therapeutics Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Kymera Therapeutics stock have an average target of 55.27, with a low estimate of 36 and a high estimate of 74. The average target predicts an increase of 50.15% from the current stock price of 36.81.
Analyst Consensus: Buy
* Price targets were last updated on Jan 21, 2025.
Analyst Ratings
The average analyst rating for Kymera Therapeutics stock from 15 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 5 | 5 | 5 |
| Buy | 5 | 5 | 6 | 7 | 7 | 7 |
| Hold | 4 | 4 | 4 | 4 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 14 | 16 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens & Co. | Stephens & Co. | Buy Reiterates $60 | Buy | Reiterates | $60 | +63.00% | Jan 21, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $60 | Buy | Maintains | $60 | +63.00% | Dec 27, 2024 |
| BTIG | BTIG | Strong Buy Initiates $60 | Strong Buy | Initiates | $60 | +63.00% | Dec 10, 2024 |
| BMO Capital | BMO Capital | Hold Initiates $55 | Hold | Initiates | $55 | +49.42% | Dec 6, 2024 |
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $38 → $57 | Hold → Buy | Upgrades | $38 → $57 | +54.85% | Dec 2, 2024 |
Financial Forecast
Revenue This Year
52.14M
from 78.59M
Decreased by -33.65%
Revenue Next Year
69.29M
from 52.14M
Increased by 32.89%
EPS This Year
-2.91
from -2.52
EPS Next Year
-3.11
from -2.91
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 78.8M | 171.2M | 171.2M | |||
| Avg | 52.1M | 69.3M | 61.0M | |||
| Low | 41.2M | 14.7M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 0.2% | 228.2% | 147.0% | |||
| Avg | -33.7% | 32.9% | -12.0% | |||
| Low | -47.6% | -71.8% | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.24 | -1.58 | -2.14 | |||
| Avg | -2.91 | -3.11 | -3.54 | |||
| Low | -3.06 | -4.27 | -6.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.